EACS 2015: Dual Therapy with Protease Inhibitors and Lamivudine Suppresses HIV
- Details
- Category: Approved HIV Drugs
- Published on Monday, 23 November 2015 00:00
- Written by Liz Highleyman
Dual antiretroviral regimens consisting of only a boosted HIV protease inhibitor (lopinavir/ritonavir or atazanavir) and a single inexpensive and well-tolerated NRTI may be enough to achieve and maintain HIV suppression in a most patients starting antiretroviral therapy (ART) for the first time or switching from a standard triple regimen, according to a pair of studies presented at the EACS 15th European AIDS Conference last month in Barcelona.
EACS 2015: Does Low-level HIV Viral Load Raise the Risk of Disease Progression and Comorbidities?
- Details
- Category: HIV Disease Progression
- Published on Wednesday, 04 November 2015 00:00
- Written by Liz Highleyman
HIV-positive people with detectable but low viral load -- in the range of 50 to 500 or 1000 copies/mL -- may continue to have a higher risk of AIDS-related events, but their likelihood of experiencing serious non-AIDS events including heart, liver, and kidney disease did not appear to increase, according to a pair of Italian studies presented at the 15th European AIDS Conference last month in Barcelona.
EACS 2015: Majority of Migrants with HIV in Europe May Have Acquired Virus in New Country
- Details
- Category: HIV/AIDS Epidemiology & Mortality
- Published on Monday, 02 November 2015 00:00
- Written by Gus Cairns
A study presented at the 15th European AIDS Conference last month in Barcelona found evidence that the majority of migrants living with HIV in Europe, and who were diagnosed less than 5 years ago, probably acquired the virus in their host country rather than the one in which they were born. The aMASE (Advancing Migrant Access to Health Services in Europe) study found that the proportion of people with a documented or probable date of HIV infection later than their move to, or within, Europe was higher than those with a documented or probable pre-migration infection date, and that this applied to all risk groups, all areas of origin, and both sexes.
EACS 2015: London Clinic Survey Shows Impact of Chemsex on Condom and PEP Use
- Details
- Category: HIV Prevention
- Published on Monday, 02 November 2015 00:00
- Written by Keith Alcorn
A survey of gay men in London using drugs during sex -- known as "chemsex" --has shown high levels of unprotected sex and hepatitis C among both HIV-positive and HIV-negative men, high levels of post-exposure prophylaxis (PEP) use, and a high frequency of injection drug use, according to research presented at the 15th European AIDS Conference last month in Barcelona.
EACS 2015: Newest MDR-TB Drug Prices Could Fall by Up to 95% Through Generic Production
- Details
- Category: Tuberculosis (TB)
- Published on Monday, 02 November 2015 00:00
- Written by Keith Alcorn
The cost of newer drugs for the treatment of multidrug-resistant tuberculosis (MDR-TB) could be cut by up to 95% if generic production of patented products could be achieved in the same way as for antiretroviral drugs, according to a study presented at the 15th European AIDS Conference last month in Barcelona. Price reductions might permit a 10-fold increase in the number of people who can be treated for MDR-TB within current budgets, without any new funding, the study suggests.
More Articles...
- EACS 2015: TB Death Rate 4-Fold Higher in Eastern Europe Due to Lack of Treatment after Diagnosis
- EACS 2015: Hepatitis C Incidence Remains Stable Among HIV-Positive Gay Men in Europe
- EACS 2015: Risk of Heart Attack Rises with Length of HIV Infection, Regardless of Age
- EACS 2015: Successful Hepatitis C Treatment Lowers Risk of Death for HIV/HCV Coinfected People
- EACS 2015: 3-Month Isoniazid/Pyrazinamide Regimen Prevents TB in People with HIV
- EACS 2015: Sofosbuvir/ Ledipasvir for 8 Weeks Cures Most Hard-to-Treat Hepatitis C in Real Life
- Coverage of the 15th European AIDS Conference
- EACS 2015: START Substudies Show More Bone Loss with Early ART, But No Differences in Lung or Neurocognitive Function
- EACS 2015: HIV Maturation Inhibitor BMS-955176 Shows Good Safety and Efficacy in Phase 2a Trial
- EACS 2015: With EACS Release, All International HIV Treatment Guidelines Agree on When to Start
- EACS 2015: When Will Europe Get PrEP?
- EACS 2015: TAF Single-Tablet Regimen Shows Good Efficacy, Improved Kidney and Bone Safety
- EACS 2015: Can Dolutegravir Dual Therapy or Monotherapy Keep HIV Suppressed?
- EACS 2015: Benefits of Early HIV Treatment Are Clear, But Issues Raised by START and D:A:D Still Unresolved
- EACS 2015: Modest Bone Loss Seen in Young Men Taking Truvada for Pre-Exposure Prophylaxis
- EACS 2015: Can Europe Reach the 90-90-90 Target for HIV Treatment by 2020?
Web Design and Development by